NCT06500494View on ClinicalTrials.gov

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

RecruitingOBSERVATIONAL
Enrollment

368

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Advanced Breast Cancer
Interventions
DRUG

Vinorelbine Tartrate Oral

The recommended dosage for oral vinorelbine is 60 mg/m² of body surface area (BSA) administered once weekly for the first three weeks, followed by 80 mg/m² of BSA for the following weekly administration.

Trial Locations (3)

16000

RECRUITING

Centre Hospitalo-Universitaire Mustapha, Hopital Mustapha, Place du 1er Mai 1945, Sidi M'Hamed, Algiers

20052

RECRUITING

Azienda Ospedaliera San Gerardo U.O. Oncologia Medica, Monza

360060

RECRUITING

Tianjing Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT06500494 - To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment | Biotech Hunter | Biotech Hunter